Preoperative platelet count in pancreas cancer: a prognostic factor?
To determine whether preoperative platelet count influenced the prognosis for surgical treatment of pancreas cancer. Retrospective study of 144 patients operated on for pancreatic cancer: 49 with adenocarcinoma, operable with curative intent (group A), 86 in whom palliative resection or bypass was done (group B), and 9 in whom exploratory laparotomy was done. Preoperative platelet count was done for all patients. Groups A and B were divided into 2 subgroups (> 200,000 platelets/mm3 and < 200,000 platelets/mm3), and an additional subgroup was established for patients with > 300,000 platelets/mm3. Survival was analyzed in the resulting subgroups. Among patients who underwent curative resection, statistical analysis revealed significantly better survival (p < 0.05) in patients with a platelet count > 200,000 platelets/mm3 and a very significant difference (p < 0.01) in the 300,000 platelets/mm3 subgroup. No differences were found in the subgroups of patients who underwent palliative surgery. Preoperative platelet count may represent a prognostic factor in patients with pancreatic cancer operated on with curative intent. Our findings justify the need for clinical trials of antiangiogenic therapy.